PARIS--(BUSINESS WIRE)--June 30, 2006--BioAlliance Pharma SA (Paris:BIO - News), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today the presentation of preliminary results from its Doxorubicin Transdrug® Phase I/II clinical trial for primary liver cancer. Dr Jean-Francois Dufour-Lamartinie, Director of Clinical Research in Oncology at BioAlliance, will present the results at the 12th ISVHLD (12th International Symposium on Viral Hepatitis and Liver Disease) in Paris July 1-5.
